Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LMAT NASDAQ:LQDA NASDAQ:PRCT NASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLMATLeMaitre Vascular$95.62-1.5%$88.92$71.42▼$109.58$2.16B0.79188,972 shs77,503 shsLQDALiquidia Technologies$27.80-0.6%$20.74$8.75▼$29.94$2.39B0.221.82 million shs2.08 million shsPRCTPROCEPT BioRobotics$39.52+1.5%$48.37$37.12▼$103.81$2.20B1.031.01 million shs789,738 shsSIBNSiBone$16.04-0.6%$16.82$11.70▼$20.05$691.97M0.81420,834 shs253,552 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLMATLeMaitre Vascular-0.43%+1.79%+5.19%+16.07%+10.23%LQDALiquidia Technologies-3.02%+1.08%+36.82%+86.78%+207.64%PRCTPROCEPT BioRobotics-4.33%-3.11%+1.33%-39.41%-49.19%SIBNSiBone-0.98%-3.24%+2.87%-15.55%+6.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLMATLeMaitre Vascular$95.62-1.5%$88.92$71.42▼$109.58$2.16B0.79188,972 shs77,503 shsLQDALiquidia Technologies$27.80-0.6%$20.74$8.75▼$29.94$2.39B0.221.82 million shs2.08 million shsPRCTPROCEPT BioRobotics$39.52+1.5%$48.37$37.12▼$103.81$2.20B1.031.01 million shs789,738 shsSIBNSiBone$16.04-0.6%$16.82$11.70▼$20.05$691.97M0.81420,834 shs253,552 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLMATLeMaitre Vascular-0.43%+1.79%+5.19%+16.07%+10.23%LQDALiquidia Technologies-3.02%+1.08%+36.82%+86.78%+207.64%PRCTPROCEPT BioRobotics-4.33%-3.11%+1.33%-39.41%-49.19%SIBNSiBone-0.98%-3.24%+2.87%-15.55%+6.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLMATLeMaitre Vascular 2.40Hold$97.602.07% UpsideLQDALiquidia Technologies 3.00Buy$32.1115.51% UpsidePRCTPROCEPT BioRobotics 2.89Moderate Buy$73.2285.28% UpsideSIBNSiBone 3.00Buy$23.6747.55% UpsideCurrent Analyst Ratings BreakdownLatest SIBN, LQDA, PRCT, and LMAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025PRCTPROCEPT BioRoboticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$60.008/15/2025LQDALiquidia TechnologiesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$43.008/13/2025LQDALiquidia TechnologiesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$33.00 ➝ $41.008/13/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $31.008/12/2025LQDALiquidia TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $36.008/11/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$25.008/7/2025PRCTPROCEPT BioRoboticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$75.00 ➝ $58.008/7/2025PRCTPROCEPT BioRoboticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$80.00 ➝ $55.008/6/2025LMATLeMaitre VascularCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$92.00 ➝ $95.008/6/2025LMATLeMaitre VascularBarrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$95.008/5/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$25.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLMATLeMaitre Vascular$219.86M9.85$2.34 per share40.81$15.00 per share6.37LQDALiquidia Technologies$14M170.95N/AN/A$0.91 per share30.55PRCTPROCEPT BioRobotics$224.50M9.79N/AN/A$7.71 per share5.13SIBNSiBone$167.18M4.14N/AN/A$3.98 per share4.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLMATLeMaitre Vascular$44.04M$2.0646.4244.062.5120.08%13.67%9.14%10/30/2025 (Estimated)LQDALiquidia Technologies-$130.39M-$1.70N/AN/AN/A-732.17%-232.96%-60.81%11/12/2025 (Estimated)PRCTPROCEPT BioRobotics-$91.41M-$1.55N/AN/AN/A-30.60%-23.73%-17.34%10/27/2025 (Estimated)SIBNSiBone-$30.91M-$0.56N/AN/AN/A-12.83%-14.20%-10.38%11/11/2025 (Estimated)Latest SIBN, LQDA, PRCT, and LMAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025LQDALiquidia Technologies-$0.43-$0.49-$0.06-$0.49$3.90 million$8.84 million8/6/2025Q2 2025PRCTPROCEPT BioRobotics-$0.41-$0.35+$0.06-$0.35$75.67 million$79.18 million8/5/2025Q2 2025LMATLeMaitre Vascular$0.57$0.60+$0.03$0.60$62.48 million$63.15 million8/4/2025Q2 2025SIBNSiBone-$0.19-$0.14+$0.05-$0.14$48.12 million$48.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLMATLeMaitre Vascular$0.800.83%N/A38.83%14 YearsLQDALiquidia TechnologiesN/AN/AN/AN/AN/APRCTPROCEPT BioRoboticsN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ALatest SIBN, LQDA, PRCT, and LMAT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/30/2025LMATLeMaitre Vascularquarterly$0.200.9%8/21/20258/21/20259/4/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLMATLeMaitre Vascular0.4613.9611.74LQDALiquidia Technologies9.842.492.41PRCTPROCEPT BioRobotics0.139.217.86SIBNSiBone0.218.387.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLMATLeMaitre Vascular84.64%LQDALiquidia Technologies64.54%PRCTPROCEPT BioRobotics89.46%SIBNSiBone98.11%Insider OwnershipCompanyInsider OwnershipLMATLeMaitre Vascular9.50%LQDALiquidia Technologies30.10%PRCTPROCEPT BioRobotics17.40%SIBNSiBone3.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLMATLeMaitre Vascular49022.64 million20.49 millionOptionableLQDALiquidia Technologies5086.09 million60.18 millionOptionablePRCTPROCEPT BioRobotics43055.64 million45.96 millionOptionableSIBNSiBone35043.14 million41.46 millionOptionableSIBN, LQDA, PRCT, and LMAT HeadlinesRecent News About These CompaniesSI-BONE, Inc. (SIBN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9 at 12:08 PM | seekingalpha.comTrexquant Investment LP Has $1.62 Million Holdings in SiBone $SIBNSeptember 8 at 3:52 AM | marketbeat.comGranahan Investment Management LLC Decreases Holdings in SiBone $SIBNSeptember 7 at 6:19 AM | marketbeat.comFirst Light Asset Management LLC Acquires 475,426 Shares of SiBone $SIBNSeptember 4, 2025 | marketbeat.comParadigm Capital Management Inc. NY Trims Stock Holdings in SiBone $SIBNSeptember 2, 2025 | marketbeat.comWalleye Capital LLC Buys Shares of 80,910 SiBone $SIBNSeptember 2, 2025 | marketbeat.comChamplain Investment Partners LLC Decreases Stake in SiBone $SIBNAugust 30, 2025 | marketbeat.comVanguard Group Inc. Increases Holdings in SiBone $SIBNAugust 29, 2025 | marketbeat.comAlphaQuest LLC Purchases 25,764 Shares of SiBone $SIBNAugust 28, 2025 | marketbeat.comRussell Investments Group Ltd. Has $2.83 Million Stake in SiBone $SIBNAugust 27, 2025 | marketbeat.comSI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025August 26, 2025 | globenewswire.comAmerican Century Companies Inc. Purchases 264,254 Shares of SiBone $SIBNAugust 23, 2025 | marketbeat.com1,326,100 Shares in SiBone $SIBN Acquired by Nuveen LLCAugust 22, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) SVP Sells $52,065.56 in StockAugust 21, 2025 | insidertrades.comTocqueville Asset Management L.P. Has $3.58 Million Stake in SiBone (NASDAQ:SIBN)August 19, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) Director John Gordon Freund Sells 12,132 SharesAugust 12, 2025 | marketbeat.comInsider Selling: SiBone (NASDAQ:SIBN) Director Sells 12,132 Shares of StockAugust 12, 2025 | insidertrades.comSiBone (NASDAQ:SIBN) Stock Rating Lowered by Wall Street ZenAugust 10, 2025 | marketbeat.comFY2025 EPS Estimates for SiBone Boosted by Cantor FitzgeraldAugust 9, 2025 | marketbeat.comSI-Bone Reports Strong Q2 2025 Financial ResultsAugust 5, 2025 | msn.comSI-BONE, Inc. (SIBN) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSIBN, LQDA, PRCT, and LMAT Company DescriptionsLeMaitre Vascular NASDAQ:LMAT$95.62 -1.45 (-1.49%) Closing price 04:00 PM EasternExtended Trading$95.54 -0.09 (-0.09%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.Liquidia Technologies NASDAQ:LQDA$27.80 -0.18 (-0.64%) Closing price 04:00 PM EasternExtended Trading$27.98 +0.18 (+0.63%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.PROCEPT BioRobotics NASDAQ:PRCT$39.52 +0.60 (+1.54%) Closing price 04:00 PM EasternExtended Trading$40.05 +0.53 (+1.34%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.SiBone NASDAQ:SIBN$16.04 -0.09 (-0.56%) Closing price 04:00 PM EasternExtended Trading$16.04 0.00 (0.00%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
